Clinical Trial Update: A Study to Assess the Effect of Repeat Doses of GSK962040 on the Pharmacokinetics of L-DOPA in Subjects With Parkinson's Disease Exhibiting Delayed Gastric Emptying [Phase 2]

View source ↗

Summary

Phase 2 study assessing repeat dosing of GSK962040 on the pharmacokinetics of L-DOPA in Parkinson's disease patients with delayed gastric emptying (gastroparesi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastroparesis
• Parkinson Disease

Drugs mentioned

• GSK962040
• L-Dopa (Levodopa)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Gastroparesis | Phase 2 | Status: COMPLETED | Results posted: 2017-02-06